Elixiron Immunotherapeutics website screenshot

Elixiron Immunotherapeutics

Elixiron Immunotherapeutics (Cayman) Limited is a clinical-stage biopharmaceutical company founded in 2017, with offices in Taipei, Taiwan and Cambridge, Massachusetts, developing precision immunotherapies for neuroinflammation, autoimmune disease and cancer. Its clinical pipeline is led by enrupatinib (EI-1071), a small-molecule CSF-1R inhibitor in development for Alzheimer's disease and other neurodegenerative indications, and EI-001, a fully human anti-interferon-gamma monoclonal antibody in Phase 2 for vitiligo, alongside preclinical EI-012 (anti-CD36) and EI-220 (mRNA) oncology programs. The company publishes a corporate and investor-relations website only: there is no developer portal, public API, SDK, webhook surface or machine-readable specification of any kind on its own hosts.

Elixiron Immunotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunotherapy, and Life Sciences.

Elixiron Immunotherapeutics’ developer surface includes product news and 6 more developer resources.

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0
0 APIs
CompanyBiotechnologyPharmaceuticalsImmunotherapyLife SciencesClinical TrialsHealthcareTaiwan

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/elixiron-immunotherapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

Access & Security 1

Authentication, authorization, and security posture

Operate 1

Status, limits, changes, and where to get help

Company 4

The organization behind the API

Source (apis.yml)

apis.yml Raw ↑
aid: elixiron-immunotherapeutics
name: Elixiron Immunotherapeutics
description: 'Elixiron Immunotherapeutics (Cayman) Limited is a clinical-stage biopharmaceutical company founded in 2017,
  with offices in Taipei, Taiwan and Cambridge, Massachusetts, developing precision immunotherapies for neuroinflammation,
  autoimmune disease and cancer. Its clinical pipeline is led by enrupatinib (EI-1071), a small-molecule CSF-1R inhibitor
  in development for Alzheimer''s disease and other neurodegenerative indications, and EI-001, a fully human anti-interferon-gamma
  monoclonal antibody in Phase 2 for vitiligo, alongside preclinical EI-012 (anti-CD36) and EI-220 (mRNA) oncology programs.
  The company publishes a corporate and investor-relations website only: there is no developer portal, public API, SDK, webhook
  surface or machine-readable specification of any kind on its own hosts.'
url: https://raw.githubusercontent.com/api-evangelist/elixiron-immunotherapeutics/refs/heads/main/apis.yml
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://elixiron.com/dist/images/common/og.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunotherapy
- Life Sciences
- Clinical Trials
- Healthcare
- Taiwan
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/elixiron-immunotherapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/elixiron-immunotherapeutics-llms.txt
- type: Website
  url: https://elixiron.com/
- type: About
  url: https://elixiron.com/about.php
- type: Contact
  url: https://elixiron.com/contact.php
- type: News
  url: https://elixiron.com/news.php
- type: LinkedIn
  url: https://www.linkedin.com/company/elixiron-immunotherapeutics
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Elixiron Immunotherapeutics is a clinical-stage biopharmaceutical company whose only production host, elixiron.com,
    serves a PHP corporate and investor-relations site whose 57-URL sitemap contains no developer, API or documentation page
    at all.
  evidence:
  - url: https://elixiron.com/sitemap.xml
    status: 200
  - url: https://elixiron.com/openapi.json
    status: 404
  - url: https://elixiron.com/.well-known/agent-card.json
    status: 404
  - url: https://elixiron.com/llms.txt
    status: 404
  checked: '2026-08-12'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/elixiron-immunotherapeutics"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/elixiron-immunotherapeutics/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/elixiron-immunotherapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

A second provider on the same verified email joins the account you already have.